Massachusetts HD 5403: A communication from the University of Massachusetts Medical School (see Section 43(f) of Chapter 75 of the General Laws) submitting a report of the activities of the MassBiologics Laboratories for fiscal year 2024

Bill Text

MassBiologics Medicine for Better

October 1, 2024
Honorable Steven T. James
Clerk of the House of Representatives
Room 145
State House
Boston, MA 02133

Honorable Michael D. Hurley
Clerk of the Senate
Room 335
State House
Boston, MA 02133
Dear Mr. James and Mr. Hurley:

As required by Chapter 75, Section 43(f), we are pleased to “submit to the Clerks of the Senate and the
House of Representatives, a report of the activities of the University of Massachusetts laboratories within
ninety days after the end of the fiscal year.” This is the twenty-seventh year of such annual report required
by the legislation, which transitioned the biologic laboratories of the state laboratory institute from the
Department of Public Health to the University of Massachusetts.

If you have any questions, please contact Executive Vice Chancellor John C. Lindstedt, UMass Chan
Medical School, 55 Lake Ave. North, Worcester, MA 01655, (508) 856-2198.

Sincerely,

Michael F. Collins, M.D.
Chancellor
University of Massachusetts Chan Medical School

John C. Lindstedt
Executive Vice Chancellor, A&F
University of Massachusetts Chan Medical School

460 Walk Hill Street - Boston, MA 02126
P (617) 474-3000
www.massbiologics.org
Docusign Envelope ID: C67BF5B9-7904-437B-82C0-2685758E9D05

1

A REPORT OF THE ACTIVITIES OF MASSBIOLOGICS
FISCAL YEAR 2024

AS REQUIRED BY CHAPTER 75, SECTION 43(F)

SUBMITTED TO
CLERK OF THE HOUSE OF REPRESENTATIVES

&
CLERK OF THE SENATE

October 1, 2024

BY
MASSBIOLOGICS of the
UNIVERSITY OF MASSACHUSETTS CHAN MEDICAL SCHOOL
Docusign Envelope ID: C67BF5B9-7904-437B-82C0-2685758E9D05

2
TABLE OF CONTENTS
1. INTRODUCTION. ..... ...... ..... ...... ..... ...... ..... ...... ..... ...... ..... 3
2. PRIOR FISCAL YEAR (FY24) INFORMATION ..... ...... ..... 4
a. Patents and Licensing ...... ..... ...... ..... ...... ..... ...... ..... ...... ..... 4
b. Collaboration and CDMO Agreements entered into .... ...... ..... 4
c. Status of existing agreements, royalties and other benefits ..... 4
d. Revenues, expenditures, assets and liabilities ...... ..... ...... ..... 5
e. FY24 Statement of Revenues, Expenditures and Other Changes 7
f. FY24 Balance Sheet . ...... ..... ...... ..... ...... ..... ...... ..... ...... ..... 8
3. FINANCIAL PLANS.. ...... ..... ...... ..... ...... ..... ...... ..... ...... ..... 9
a. FY25 Projected Statement of Revenues, Expenditures and Other Changes 10
b. FY26 Projected Statement of Revenues, Expenditures and Other Changes 11
c. FY27 Projected Statement of Revenues, Expenditures and Other Changes 12
Docusign Envelope ID: C67BF5B9-7904-437B-82C0-2685758E9D05

3
1. INTRODUCTION
This report is submitted, as required by Chapter 75, Section 43(f), on the activities of the
MassBiologics of the University of Massachusetts Chan Medical School. This is the twenty-seventh
year of such annual report.
The following sections provide the required information as follows:

Part 2, Prior Fiscal Year (FY24) Information, as indicated by legislation, describes the patents and
licenses, agreements entered into, status of existing agreements, royalties and other benefits, and
expenditures, current assets and liabilities. This section includes two schedules: (1) FY24 Statement of
Revenues and Expenditures and Other Changes and (2) FY24 Balance Sheet. Included here is
information related to appropriated funds for the prior fiscal year, as required by the legislation.

Part 3, Financial Plans, presents projected revenues and expenses. A three-year projection is included.
Docusign Envelope ID: C67BF5B9-7904-437B-82C0-2685758E9D05

4
2. PRIOR FISCAL YEAR (FY24) INFORMATION
This section of the report presents the specific information indicated in the legislation related to
the prior fiscal year (FY24: July 1, 2023 - June 30, 2024). This is the twenty-seventh full year in
which MassBiologics has operated within the University of Massachusetts. The effective date of
the transfer to the University of Massachusetts was January 1, 1997.

a. Patents and Licensing
MassBiologics had two patents issued in FY24:
1) Anti-ETEC Adhesin Protein Antibodies and Methods of Use
8/22/2023 United States Patent Number 11732032
2) Anti-CfaE Antibodies and Methods of Use
11/28/2023 United States Patent Number 11827670

b. Collaboration and CDMO Service Agreements entered into:

MassBiologics Contract Development and Manufacturing Services in FY24 include:

1) Four existing clients continuing their production programs.
2) Eleven new project specific service agreements were executed in FY24. Total
CDMO revenue recognized in FY24 was $18M

c. Status of existing agreements, royalties and other benefits / challenges
MassBiologics had the following major existing agreements in FY24.

Medimmune (formerly Molecular Vaccines), license for Synagis, a therapeutic for Respiratory
Syncytial Virus (RSV) signed August 1, 1989. Medimmune is a wholly owned subsidiary of
AstraZeneca Pharmaceuticals, and divested US rights to Synagis to Swedish Orphan Biovitrum (Sobi